VIP / Vasoactive Intestinal Peptide

ID: vip

Aliases: VIP, vasoactive intestinal peptide, vasoactive intestinal polypeptide, aviptadil

Type: compound

Route/form: intracavernosal/inhaled/IV research contexts depending indication; no generic wellness route

Status: investigational_or_research

Evidence level: early human

Best data tier: early human + human controlled/review

Support scope: human

Source types: human_rct, human_trial

Linked sources: 2

Broad outcomes: Cardiovascular / lipids / blood pressure, Gut / immune / inflammation, Hormones / fertility / sexual health

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• VPAC receptor agonism
• vasodilation
• bronchoimmune and neurovascular signaling

Optimization domains

• vascular
• erectile quality
• migraine
• pulmonary
• inflammation

Research basis

• Human trial data show biologic activity in erectile and migraine-provocation contexts.
• Mechanism is clear enough to map vasodilatory and immunomodulatory claims.

Limits, risks, and missing evidence

• Vasodilation/headache/hypotension risk can be the mechanism showing up as an adverse effect.
• No generic wellness or recovery indication follows from VIP physiology.

Risk flags

• vasodilator
• hypotension
• headache migraine
• investigational
• medical supervision

Linked papers, labels, and reviews

1. A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection
   human_trial / pubmed_vip_erection_trial_1990
   Human erectile-function physiology/trial context for VIP.
2. Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial
   human_rct / pubmed_vip_migraine_rct_2021
   Human provocative physiology trial; demonstrates biologic activity and headache risk.